Docetaxel Injection, Solution
Product Images NDC 72078-040

14 FDA label images from Mylan Institutional Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Docetaxel (NDC 72078-040). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Institutional Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Docetaxel Structrual Formula (Image 14)

Docetaxel Structrual Formula (Image 14)
Chemical structure of Docetaxel (DOCETAXEL ANHYDROUS), the active ingredient in the Docetaxel 10 mg/mL injection solution by Mylan Institutional LLC.*
FDA Label Image

Figure 1: Tax316 Disease Free Survival K-m Curve (Image 04)

Figure 1: Tax316 Disease Free Survival K-m Curve (Image 04)
A Kaplan-Meier curve showing Disease-Free Survival (DFS) probability (%) over time in months. The chart compares two groups labeled TAC and FAC, with DFS probability decreasing over approximately 70 months. The TAC group shows generally higher DFS probabilities compared to the FAC group throughout the timeline.*
FDA Label Image

Figure 2: Tax316 Overall Survival K-m Curve (Image 05)

Figure 2: Tax316 Overall Survival K-m Curve (Image 05)
A survival probability curve chart comparing two treatment groups labeled TAC and FAC. The x-axis represents survival time in months up to 66 months, and the y-axis shows survival probability as a percentage from 0 to 100%. The chart displays survival trends over time for both groups, with TAC depicted by a solid line and FAC by a dotted line.*
FDA Label Image

Figure 3: Tax317 Survival K-m Curves (Docetaxel 75 mg/m2 vs. Best Supportive Care)

Figure 3: Tax317 Survival K-m Curves (Docetaxel 75 mg/m2 vs. Best Supportive Care)
A survival curve chart comparing overall survival probabilities over time in months for two groups labeled T75 and BSC. The graph plots cumulative probability on the y-axis against survival time in months on the x-axis, showing a statistical significance with a log-rank p-value of 0.010.*
FDA Label Image

Figure 4: Tax320 Survival K-m Curves (Docetaxel 75 mg/m2 vs. Vinorelbine or Ifosfamide Control)

Figure 4: Tax320 Survival K-m Curves (Docetaxel 75 mg/m2 vs. Vinorelbine or Ifosfamide Control)
A survival curve graph displaying cumulative probability versus survival time in months for two groups labeled T75 and V/I. The graph includes a log-rank p-value of 0.13 and compares overall survival between these groups over a period up to 21 months.*
FDA Label Image

Figure 5: Tax327 Survival K-m Curves (Image 08)

Figure 5: Tax327 Survival K-m Curves (Image 08)
A survival probability curve graph depicting survival time in months on the horizontal axis and survival probability on the vertical axis. Two lines are plotted, labeled as T75 q3w (solid line) and M q3w (dashed line), showing changes in survival probability over approximately 30 months.*
FDA Label Image

Figure 6: Gastric Cancer Study (tax325) Time To Progression K-m Curve (Image 09)

Figure 6: Gastric Cancer Study (tax325) Time To Progression K-m Curve (Image 09)
A survival probability curve chart comparing TCF and CF treatments over time in months. The y-axis represents the probability percentage, starting at 100% and declining over a 24-month period on the x-axis. Two lines illustrate the difference in survival probabilities between TCF (solid line) and CF (dashed line).*
FDA Label Image

Figure 7: Gastric Cancer Study (tax325) Survival K-m Curve (Image 10)

Figure 7: Gastric Cancer Study (tax325) Survival K-m Curve (Image 10)
A survival probability curve chart showing survival probability (%) on the y-axis and survival time in months on the x-axis. Two legend groups are plotted: TPF and PF, illustrating comparative survival outcomes over approximately 72 months.*
FDA Label Image

Figure 8: Tax323 Progression-free Survival K-m Curve (Image 11)

Figure 8: Tax323 Progression-free Survival K-m Curve (Image 11)
A survival probability curve chart comparing two groups labeled TPF and PF over a survival time period of 0 to 72 months. The Y-axis represents survival probability as a percentage from 0 to 100%, and the X-axis indicates survival time in months. Patient numbers at risk are listed below the chart for both groups at various time points.*
FDA Label Image

Figure 9: Tax323 Overall Survival K-m Curve (Image 12)

Figure 9: Tax323 Overall Survival K-m Curve (Image 12)
Packaging label for Docetaxel Injection, USP 80 mg/8 mL (10 mg/mL) intravenous injection solution by Mylan Institutional LLC. The label indicates a multiple-dose vial, ready to add to infusion solution, with warnings for cytotoxic agent handling. Manufactured in India, branded with Novaplus trademark, and includes storage and usage instructions.*
FDA Label Image

Figure 10: Tax324 Overall Survival K-m Curve (Image 13)

Figure 10: Tax324 Overall Survival K-m Curve (Image 13)
A Kaplan-Meier survival curve chart depicting survival probability (%) over time in months. Two groups, labeled TPF (n=255) and PF (n=246), are compared, with the number of patients at risk listed below the x-axis at various time points.*
FDA Label Image

Docetaxel Injection 20 mg/2 mL Carton Label (Image 02)

Docetaxel Injection 20 mg/2 mL Carton Label (Image 02)
Packaging label for Docetaxel Injection, USP 10 mg/mL (20 mg/2 mL) solution for intravenous use, produced by Mylan Institutional LLC. The label indicates a one-vial formulation, ready for addition to infusion solution, with warnings including cytotoxic agent caution and instructions for sterile handling. The package contains 1 x 2 mL single-dose vial.*
FDA Label Image

Docetaxel Injection 80 mg/8 mL Carton Label (Image 01)

Docetaxel Injection 80 mg/8 mL Carton Label (Image 01)
Packaging label for Docetaxel Injection, USP, 80 mg per 8 mL (10 mg/mL) solution for intravenous use by Mylan Institutional LLC. The label includes dosage information, cautions such as cytotoxic agent warnings, storage instructions between 20° to 25°C, and that the vial is a 1 x 8 mL multiple-dose vial. Branding includes Novaplus and detailed preparation guidance is visible.*
FDA Label Image

Docetaxel Injection 160 mg/16 mL Carton Label (Image 03)

Docetaxel Injection 160 mg/16 mL Carton Label (Image 03)
Packaging label for Docetaxel Injection, USP 10 mg/mL (160 mg/16 mL), an intravenous solution distributed by Mylan Institutional LLC. The label indicates this is a 1 x 16 mL multiple-dose vial, ready to add to infusion solution, with a warning of cytotoxicity and instructions to check concentration prior to preparation. The label also includes storage, formulation, and usage details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.